Tao Synergies Inc (TAOX)

$8.40 -0.80 (-8.65%)
Market Cap 11.67M
Revenue (ttm) 0.00
Net Income (ttm) -12.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 249,700
Avg Vol 1,309,040
Day's Range N/A - N/A
Shares Out 1.39M
Stochastic %K 68%
Beta 1.87
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
d_risk
d_risk Aug. 17 at 4:37 PM
$TAOX - TAO Synergies Inc. - 10Q - Updated Risk Factors TAOX flags major new risks: heavy dependence on TAO price and liquidity, execution risk on its crypto strategy, need for more financing, concentrated exposure to Bittensor’s technical, governance, and regulatory uncertainties, reliance on key personnel and third parties, and broad regulatory, tax, and security threats tied to crypto asset operations. #Cryptocurrency #KeyPersonnelDependence #RegulatoryUncertainty #FinancingNeeds #ExecutionRisk 🟢 Added 🟠 Removed https://d-risk.ai/TAOX/10-Q/2025-08-14
0 · Reply
SilentRider1
SilentRider1 Aug. 16 at 9:39 AM
$TAOX if they find the money will fly
0 · Reply
SilentRider1
SilentRider1 Aug. 15 at 9:56 PM
$TAOX super tao
0 · Reply
SilentRider1
SilentRider1 Aug. 15 at 9:49 PM
$TAOX scam
0 · Reply
SilentRider1
SilentRider1 Aug. 15 at 9:54 AM
$TAOX so ?
1 · Reply
SnoopyPotter
SnoopyPotter Aug. 14 at 9:56 PM
$TAOX files S-3 for $100M shelf offering! Big move for the AI-crypto play—planning to issue common stock, preferred stock, debt, warrants, or units. Focus: staking $TAO (Bittensor’s AI token) for revenue & growth. Public float ~$28.4M, stock at $9.56 $XTAO $DTAO
0 · Reply
FilingTracker
FilingTracker Aug. 14 at 8:53 PM
$TAOX $100 million offering to buy more $TAO: https://x.com/trackfilings/status/1956096891344838737?s=46&t=Jiey-eytw2rowAPgxZ94Yg
0 · Reply
Learninghow
Learninghow Aug. 14 at 2:34 PM
$OBLG $TAOX I’ve always heard if you judge someone you are really judging something you don’t like about yourself. Choose wisely who you listen to because some want you to win while others want you to fail. Oblong has COH and it will only multiply with TAOX.
0 · Reply
TaoistTrader
TaoistTrader Aug. 14 at 1:53 PM
$TAOX took half off in my trading account. still long, but smaller now.
0 · Reply
SnoopyPotter
SnoopyPotter Aug. 14 at 1:10 PM
Yo, $TAOX short sellers, listen up! Days to Cover is only 1.05 days for 417,995 shorted shares (~398K daily vol), so covering sounds quick, right? Hold up! This stock’s got high squeeze vibes (84/100 score) ‘cause:31.94% of the float is shorted—yep, a big chunk! 107.97% borrow fee—ouch, that’s pricey to stay short! 61.44% dark pool action—big players moving shares on the down-low. Price swinging wild: $9.56 (Aug 13) to $8.73 (Aug 14). Watch out, shorts! Those dark pool trades and crazy costs could spark a squeeze. #TAOX #ShortSqueeze
0 · Reply
Latest News on TAOX
TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 6 weeks ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 7 weeks ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 7 weeks ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 2 months ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 8 months ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 1 year ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 1 year ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 1 year ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 1 year ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 2 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 2 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Dec 9, 2022, 11:50 AM EST - 2 years ago

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 2 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 3 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 3 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 16, 2021, 11:07 PM EST - 4 years ago

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Nov 15, 2021, 9:28 AM EST - 4 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Oct 5, 2021, 9:14 AM EDT - 4 years ago

Rebuilding Connections, Fostering Growth: Synaptogenix Could Be A Beacon of Hope for Patients With Neurological Diseases

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Sep 10, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Participation at the H.C. Wainwright 23rd Annual Global Investment Conference

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Aug 5, 2021, 10:00 AM EDT - 4 years ago

Synaptogenix Signs Memorandum Of Understanding with Nemours A.I. DuPont Hospital to Initiate Trial Using Bryostatin, Under Orphan Drug Status, to Treat Fragile X Syndrome

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Jul 26, 2021, 1:47 PM EDT - 4 years ago

Synaptogenix Stock Drops After Unveiling Analyses Of Alzheimer's Candidate

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Jul 26, 2021, 9:15 AM EDT - 4 years ago

Synaptogenix Discloses Positive Results of Further Bryostatin Trial Analyses in Presentation at Alzheimer's Association International Conference 2021

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Jul 21, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Conference Call to Discuss AAIC Abstract Findings

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Jul 14, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix to Present Data at Alzheimer's Association International Conference 2021 Highlighting Bryostatin Restores Cognitive Function Above Baseline

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Jul 7, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces Regenerative Patent Award to Treat Alzheimer's Disease

Synaptogenix: The Next Big Thing In Alzheimer's

Jun 16, 2021, 4:06 PM EDT - 4 years ago

Synaptogenix: The Next Big Thing In Alzheimer's

Synaptogenix Announces $12.5 Million Private Placement

Jun 14, 2021, 9:00 AM EDT - 4 years ago

Synaptogenix Announces $12.5 Million Private Placement

Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

Jun 9, 2021, 1:25 PM EDT - 4 years ago

Synaptogenix's Alzheimer's Candidate Displays Signs Of Safety In Mid-Stage Study

d_risk
d_risk Aug. 17 at 4:37 PM
$TAOX - TAO Synergies Inc. - 10Q - Updated Risk Factors TAOX flags major new risks: heavy dependence on TAO price and liquidity, execution risk on its crypto strategy, need for more financing, concentrated exposure to Bittensor’s technical, governance, and regulatory uncertainties, reliance on key personnel and third parties, and broad regulatory, tax, and security threats tied to crypto asset operations. #Cryptocurrency #KeyPersonnelDependence #RegulatoryUncertainty #FinancingNeeds #ExecutionRisk 🟢 Added 🟠 Removed https://d-risk.ai/TAOX/10-Q/2025-08-14
0 · Reply
SilentRider1
SilentRider1 Aug. 16 at 9:39 AM
$TAOX if they find the money will fly
0 · Reply
SilentRider1
SilentRider1 Aug. 15 at 9:56 PM
$TAOX super tao
0 · Reply
SilentRider1
SilentRider1 Aug. 15 at 9:49 PM
$TAOX scam
0 · Reply
SilentRider1
SilentRider1 Aug. 15 at 9:54 AM
$TAOX so ?
1 · Reply
SnoopyPotter
SnoopyPotter Aug. 14 at 9:56 PM
$TAOX files S-3 for $100M shelf offering! Big move for the AI-crypto play—planning to issue common stock, preferred stock, debt, warrants, or units. Focus: staking $TAO (Bittensor’s AI token) for revenue & growth. Public float ~$28.4M, stock at $9.56 $XTAO $DTAO
0 · Reply
FilingTracker
FilingTracker Aug. 14 at 8:53 PM
$TAOX $100 million offering to buy more $TAO: https://x.com/trackfilings/status/1956096891344838737?s=46&t=Jiey-eytw2rowAPgxZ94Yg
0 · Reply
Learninghow
Learninghow Aug. 14 at 2:34 PM
$OBLG $TAOX I’ve always heard if you judge someone you are really judging something you don’t like about yourself. Choose wisely who you listen to because some want you to win while others want you to fail. Oblong has COH and it will only multiply with TAOX.
0 · Reply
TaoistTrader
TaoistTrader Aug. 14 at 1:53 PM
$TAOX took half off in my trading account. still long, but smaller now.
0 · Reply
SnoopyPotter
SnoopyPotter Aug. 14 at 1:10 PM
Yo, $TAOX short sellers, listen up! Days to Cover is only 1.05 days for 417,995 shorted shares (~398K daily vol), so covering sounds quick, right? Hold up! This stock’s got high squeeze vibes (84/100 score) ‘cause:31.94% of the float is shorted—yep, a big chunk! 107.97% borrow fee—ouch, that’s pricey to stay short! 61.44% dark pool action—big players moving shares on the down-low. Price swinging wild: $9.56 (Aug 13) to $8.73 (Aug 14). Watch out, shorts! Those dark pool trades and crazy costs could spark a squeeze. #TAOX #ShortSqueeze
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Aug. 13 at 6:22 PM
$TAOX
0 · Reply
TheArtOfStockWar
TheArtOfStockWar Aug. 13 at 6:12 PM
$TAOX sold. Done. But $ATNF ….when will you obey me! @mhparvez
1 · Reply
TaoistTrader
TaoistTrader Aug. 13 at 6:06 PM
$TAO.X $TAOX this is getting a little silly 😅
0 · Reply
SnoopyPotter
SnoopyPotter Aug. 13 at 5:57 PM
$TAOX Hello people!- The elevated borrow fees (107.67% APR) and declining share availability indicate shorts are under pressure, which could amplify volatility. Long holders might see gains if the squeeze succeeds. Positive Earnings report coming out 8/13 hopefully
0 · Reply
MasterOfMyDomains
MasterOfMyDomains Aug. 13 at 5:42 PM
$TAOX I think you are in the wrong board. You probably belong in the weed stocks....
0 · Reply
MPSEnt
MPSEnt Aug. 13 at 1:28 PM
$OBLG $TAOX I agree. They share John Schechter as a board member of both companies. TAOX maintains a larger TAO position and seems to be mostly a holding company. OBLG offers the tech background for future AI development on the Bittensor platform. It's a marriage made in heaven, but if not a merger...definitely a business collaboration is possible. Both companies have entirely pivoted to AI/TAO Bittensor to capture Trumps ctypto/AI revolution. It's all just the beginning for both companies. Boom, boom soon.
0 · Reply
Learninghow
Learninghow Aug. 13 at 12:15 PM
$OBLG $TAOX these two are tied together. With oblong earnings today, and their investment with taox of $8+ million, something could be brewing today with oblong.
0 · Reply
SnoopyPotter
SnoopyPotter Aug. 13 at 2:14 AM
$TAOX TAO Synergies Inc. (TAOX) is expected to report its next earnings on August 18, 2025, after market close. Some sources also list August 13, 2025, or August 11, 2025, but the August 18th date is the most consistently mentioned for the upcoming report. This date is based on historical reporting patterns and is subject to revision if the company announces a different date.
0 · Reply
TheArtOfStockWar
TheArtOfStockWar Aug. 13 at 12:21 AM
$TAOX remember to sell at 10. Low risk. @mhparvez
0 · Reply
SnoopyPotter
SnoopyPotter Aug. 13 at 12:16 AM
$TAOX wonder if earnings report is happening tomorrow 8/13
0 · Reply
SilentRider1
SilentRider1 Aug. 12 at 7:39 PM
$TAOX Need 20 bucks
2 · Reply
Munkeynutzzz
Munkeynutzzz Aug. 12 at 3:54 PM
$TAOX
0 · Reply